Financials

News Discussions Technicals Forecast Seasonals

2315 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to BIOCYTOGEN PHARMACEUTICALS (BEIJING operating, investing, and financing activities

2315 free cash flow for H1 24 is -1.14 M HKD. For 2023, 2315 free cash flow was -232.67 M HKD and operating cash flow was -92.76 M HKD.

‪0.00‬

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: HKD

TTM

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—